Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

Breakthrough May Revolutionize Preclinical Imaging

By BiotechDaily International staff writers
Posted on 07 Oct 2013
Image: The magnetic particle imaging (MPI) system is an entirely new technology for preclinical imaging (Photo courtesy of Bruker).
Image: The magnetic particle imaging (MPI) system is an entirely new technology for preclinical imaging (Photo courtesy of Bruker).
A novel imaging technique for disease studies, translational research, and drug discovery will soon be made available to the biotechnology research community.

Bruker (Billerica, MA, USA) has announced the world’s first magnetic particle imaging (MPI) system, a novel technology for preclinical imaging. The MPI tomographic imaging technique relies on the detection of the magnetic properties of iron-oxide nanoparticles injected into the bloodstream to produce three-dimensional images. The system has been used to produce images that accurately captured the real-time physiological activity of a mouse's cardiovascular system,

The Bruker preclinical MPI scanner was developed in collaboration with Royal Philips (Amsterdam, The Netherlands), in a partnership that combined Bruker’s leadership in analytical magnetic resonance instruments with Philips’ strengths in medical imaging technology. The partners will co-market the preclinical MPI scanner.

Dr. Michael Heidenreich, technical director at Bruker, said, "We are very pleased about this breakthrough in preclinical imaging and our collaboration with Philips on this exciting technology. Magnetic particle imaging is a novel imaging modality that is expected to enable scientists to address an extensive range of new issues in preclinical research. MPI nicely complements Bruker’s preclinical imaging product portfolio of now nine different modalities. The highly sensitive visualization of functional characteristics in vivo at high temporal resolution offers great potential for small animal imaging, especially when combined with high spatial resolution morphological MRI."

"Magnetic particle imaging represents a fundamentally new imaging modality with an exceptional ability to image in vivo functional behavior," said Homer Pien, chief technology officer at Philips. "We are particularly excited about its potential for providing new insights into cardiovascular disease, cancer, and stem cell therapies. Going forward, I am convinced that the results from the research studies conducted with preclinical MPI systems will provide valuable guidance for our ongoing development of a whole-body clinical MPI system."

Related Links:
Bruker
Royal Philips


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Blocking the activity of HSP101 may imprison the malaria parasite inside its protective vacuole within the red blood cell. In the electron micrograph, the malaria parasites appear in blue and uninfected red blood cells are shown in red (Photo courtesy of the [US] National Institute of Allergy and Infectious Diseases).

Heat Shock Protein Plays Critical Role in Malaria Parasite Protein Trafficking

A pair of recent papers described the molecular operators that enable the malaria parasite Plasmodium falciparum to export a large variety of proteins across the parasitophorous vacuolar membrane (PVM)... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.